丹麦制药巨头诺和诺德获得一家中国企业开发的减重疗法授权，凸显了中国生物科技产业日益向尖端领域迈进的进展。
Danish pharma giant Novo licensed a weight-loss treatment developed by a Chinese firm, highlighting advances in China’s increasingly cutting-edge biotech sector.
该疗法背后的企业恒瑞医药去年与葛兰素史克（GSK）达成了规模更大的协议，涉及包括癌症在内的多个领域的新药开发；诺和诺德此前也曾与另一家中国企业就另一种减重药签署协议。
The firm behind the treatment, Hengrui Pharma, last year reached an even bigger agreement with GSK for the development of new drugs across multiple areas, including cancer; Novo has also previously signed a deal with another Chinese company for a different weight-loss drug.
这些协议巩固了一场非凡的转型：Sinica Podcast 的 Kaiser Kuo 指出：“就在人们记忆犹新的年代，中国曾派赤脚医生深入乡村，他们背着军绿色挎包，里面装着草药和抗生素。”而阿斯利康的首席财务官最近告诉 Semafor，如今中国制药企业挑战全球制药巨头“只是时间问题”。——Prashant Rao
The agreements cement a remarkable transformation: “Within living memory, China sent barefoot doctors into the countryside with herbal remedies and antibiotics in army-green satchels,” Kaiser Kuo of the Sinica Podcast noted, whereas AstraZeneca’s chief financial officer recently told Semafor that it is now “only a question of time” before Chinese pharma companies challenge global firms. — Prashant Rao